Robert Shawah
Fondateur chez ACURX PHARMACEUTICALS, INC.
Fortune : 474 892 $ au 31/05/2024
Postes actifs de Robert Shawah
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ACURX PHARMACEUTICALS, INC. | Fondateur | 01/07/2017 | - |
| Directeur Financier/CFO | 01/07/2017 | - | |
| Comptroller/Controller/Auditor | 01/07/2017 | - |
Historique de carrière de Robert Shawah
Anciens postes connus de Robert Shawah
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Ameri100 Holdco, Inc.
 Ameri100 Holdco, Inc. MiscellaneousMiscellaneous Ameri100 Holdco, Inc. operates as an investment holding company. The company is headquartered in Delaware. | Directeur/Membre du Conseil | 01/08/2018 | 01/12/2018 |
Dipexium Pharmaceuticals, Inc.
 Dipexium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dipexium Pharmaceuticals, Inc. is a late stage pharmaceutical company, which is focused on the development and commercialization of Locilex, a potent and broad spectrum topical antibiotic peptide for the treatment of mild and moderate skin and skin structure infections. The company was founded by Robert J. DeLuccia and David P. Luci on January 14, 2010 and is headquartered in New York, NY. | Comptroller/Controller/Auditor | 01/03/2014 | 01/04/2017 |
| Treasurer | 01/03/2014 | 01/04/2017 | |
| Baldwin Pearson & Co., Inc. | Corporate Officer/Principal | 01/01/2005 | 01/01/2013 |
Formation de Robert Shawah
| Bucknell University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Comptroller/Controller/Auditor | 2 |
| Treasurer | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
| Miscellaneous | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACURX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dipexium Pharmaceuticals, Inc. is a late stage pharmaceutical company, which is focused on the development and commercialization of Locilex, a potent and broad spectrum topical antibiotic peptide for the treatment of mild and moderate skin and skin structure infections. The company was founded by Robert J. DeLuccia and David P. Luci on January 14, 2010 and is headquartered in New York, NY. | Health Technology |
| Baldwin Pearson & Co., Inc. | |
Ameri100 Holdco, Inc.
Ameri100 Holdco, Inc. MiscellaneousMiscellaneous Ameri100 Holdco, Inc. operates as an investment holding company. The company is headquartered in Delaware. | Miscellaneous |
- Bourse
- Insiders
- Robert Shawah
- Expérience
